Cadila: Among few bright spots in pharma space
Unlike many of its pharma peers, there has been a slew of goods news for Cadila Healthcare in recent times. While its Moraiya plant recently got clearance of the US FDA, Cadila has also received almost a dozen approvals for new launches in the US since September. In the last 7-8 days itself, there were five announcements on fresh approvals for new products and dosage forms. Faster launches is crucial for the US business (40 per cent of sales), given the intense pricing pressure being faced by all pharma companies, and will enable Cadila to sustain its growth rates.While the approval rate remains strong, shortage of hypertension drug, Atenolol in the US can help Cadila garner some quick gains too. In the four generic player markets, the shortage of Active Pharma Ingredients (or APIs) for the drug is proving helpful for Cadila, which is not facing any shortage. Cadila's market share has surged from 16 per cent to 47 per cent (absolute increase of 130 per cent) suggests a Credit Suisse ..06-10-2017
